Concepedia

S. Feyerabend

SF

Statistics

Publications

4

Citations

124

H-Index

4

Active since

2009

Affiliations

Clatterbridge Cancer Centre NHS Foundation Trust(Current)

S. Feyerabend is an author at Clatterbridge Cancer Centre NHS Foundation Trust specializing in cancer immunotherapy, immunotherapy, and oncology.

Publications per year

2009–2017

4

Publications

4

Results of the randomized, placebo-controlled phase I/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)

Arnulf Stenzl, S. Feyerabend, Isabel Syndikus et al. · Annals of Oncology · 2017 · 68 citations

Medicine, Immunology, Oncology +16

Final analysis of a phase I/IIa study with CV9103, an intradermally administered prostate cancer immunotherapy based on self-adjuvanted mRNA.

Hubert Kübler, Tobias Maurer, Arnulf Stenzl et al. · Journal of Clinical Oncology · 2011 · 31 citations

Medicine, Immunology, Oncology +17

1047 EARLY VERSUS DELAYED TREATMENT OF ACUTE HEPATITIS C: THE GERMAN HEP-NET ACUTE HCV-III STUDY – A RANDOMIZED CONTROLLED TRIAL

Katja Deterding, N. Grüner, Johannes Wiegand et al. · Journal of Hepatology · 2009 · 15 citations

Pharmacy, Infectious Diseases, Internal Medicine +10

A phase II study of imatinib with pioglitazone, etoricoxib, dexamethasone, and low-dose treosulfan: Combined anti-inflammatory, immunomodulatory, and angiostatic treatment in patients (pts) with castration-refractory prostate cancer (CRPC).

Albrecht Reichle, Martin Vogelhuber, S. Feyerabend et al. · Journal of Clinical Oncology · 2011 · 10 citations

Medicine, Oncology, Pharmacology +17

1–4 of 4